编者按：近年来，癌症药物研发的重心正悄然发生转变。与过去围绕成熟靶点持续进行优化迭代不同，新一轮创新更加聚焦于 如何突破长期被视为"不可成药"（undruggable）的靶点。在2025年欧洲肿瘤内科学会（ESMO）靶向抗癌治疗（TAT）大会 上，多项针对此类靶点的创新疗法首次人体研究结果相继公布，显示该领域正加速从基础探索迈向临床验证阶段。随后， Annals of Oncology对其中具有代表性的研究进行了系统梳理，重点介绍了已在人体中完成机制验证、展现出生物标志物相关信 号且具有可控安全性的候选药物，同时也涵盖多项仍处于临床前阶段、但有望突破"不可成药"限制的创新技术平台。 作为全球医药创新的赋能者，药明康德依托一体化、端到端的CRDMO平台，持续支持全球合作伙伴加速创新疗法研发进程， 致力于将更多突破性治疗方案带给癌症患者。本文将基于Annals of Oncology的相关内容，并结合公开资料，梳理当前"不可成 药"靶点领域涌现的早期突破及其潜在意义，呈现这一前沿方向的最新发展脉络。 靶点：MYC MYC长期被认为属于典型的"不可成药"靶点。其蛋白结构高度动态且缺乏稳定结合口袋，使传统小分子难以实 ...

Group 1 - The company held its second board meeting on February 10, 2026, where it approved several key proposals, including adjustments to its fundraising investment structure [1][2][4] - The board approved the addition of a new sub-project "YF550" under the "New Drug Research and Development Project" while maintaining the total investment amount unchanged [2][12] - The board also approved the establishment of a "Market Value Management System" to enhance investor returns and protect investor interests [5][6] Group 2 - The company plans to increase funding for the D-2570 project, a TYK2 inhibitor for treating autoimmune diseases, by approximately 23,210.95 million RMB to support ongoing clinical trials [16][24] - Additional funding of 4,720.00 million RMB will be allocated for the clinical research of YF087, a candidate drug in the preclinical stage [18][25] - The company will also invest 4,290.00 million RMB in YF550, another candidate drug, to prepare for its Phase I clinical trial [19][25] Group 3 - The adjustments in funding are aimed at optimizing resource allocation and ensuring that the investment aligns with the company's research and development strategy [23][26] - The market for autoimmune disease treatments is projected to grow significantly, with the global market expected to reach approximately 194.8 billion USD by 2030, indicating a strong demand for innovative therapies [27][28] - The company is focusing on developing drugs that target unmet clinical needs, particularly in the areas of autoimmune diseases and gout, which are seeing rising patient numbers [29][30]

编者按：近年来，合成致死作为一种独特的精准治疗策略，在肿瘤治疗领域受到广泛关注。这一策略通过靶向肿瘤特异性基因间依赖关系，为克服治疗耐 药性与"不可成药"靶点提供了重要突破口。作为全球医药创新的赋能平台，药明康德依托"一体化、端到端"的CRDMO赋能平台，持续协助全球合作伙伴 推进包括癌症在内的各类疾病创新疗法研发，加速创新成果向临床获益转化。值此世界癌症日，我们将通过这篇文章与各位读者分享基于合成致死策略的 疗法探索，以及药明康德一体化平台如何在不同阶段推动合成致死药物的研发。 精准击杀癌细胞 在对抗癌症的漫长征程中，科学家们一直在尝试寻找可以精准摧毁癌细胞，而不伤及正常细胞的工具。近年来，一种名为合成致死（Synthetic Lethality） 的策略受到了科学界的重点关注。 合成致死策略的基础是一对特殊的基因组合——组合中，任一基因单独失活都不会影响细胞活力，但两者同时失活则会导致细胞死亡。在许多癌细胞中， 由于特定的基因突变，这对基因中的一个已经丧失功能。因此，科学家只需设计药物来抑制另一个基因，就能在癌细胞中实现"双重失活"，从而特异性清 除癌细胞。 合成致死机制为治疗特定基因突变的肿瘤提供了革命 ...

Core Insights - Synthetic lethality drugs specifically target cancer cells while sparing normal cells, showing remarkable potential in cancer treatment and gaining importance in precision oncology [1][4][13] - The global synthetic lethality drug market is projected to reach $4.3 billion in 2024 and $4.8 billion in 2025, with the Chinese market expected to grow from 3.6 billion yuan in 2024 to 4.6 billion yuan in 2025 [1][4][13] - PARP inhibitors, a successful example of synthetic lethality, have seen global sales reach $3.072 billion in 2024, with an expected increase to $3.4 billion in 2025 [1][4][13] Market Overview - The global synthetic lethality drug market is expected to grow significantly, with a forecasted size of $4.3 billion in 2024 and $4.8 billion in 2025 [4][13] - The Chinese synthetic lethality drug market is also on the rise, projected to reach 3.6 billion yuan in 2024 and 4.6 billion yuan in 2025 [4][13] PARP Inhibitors - The first PARP inhibitor, Olaparib, has become a blockbuster drug in oncology, achieving nearly 9.3% growth in sales after 10 years on the market [1][4][13] - Global sales of PARP inhibitors are expected to reach $3.072 billion in 2024 and $3.4 billion in 2025 [1][4][13] Industry Definition and Mechanism - Synthetic lethality refers to a situation where mutations in two non-lethal genes do not affect cell survival, but simultaneous mutations lead to cell death [3][7] - The concept of synthetic lethality has been recognized in cancer cells, allowing for targeted therapies that selectively eliminate cancer cells while protecting normal tissues [3][7] Policy and Industry Chain - The industry is supported by various national policies aimed at enhancing cancer precision treatment and synthetic lethality drug development, including guidelines and reform measures [3][9] - The industry chain includes upstream biological raw materials, midstream drug development, and downstream clinical applications in hospitals and research institutions [3][9] Competitive Landscape - Since the approval of Olaparib in 2014, several other PARP inhibitors have entered the market, including Niraparib, Rucaparib, and Talazoparib, expanding treatment options for cancer patients [5][15] - The competitive landscape is evolving, with major pharmaceutical companies exploring new synthetic lethality targets, indicating a growing interest in this therapeutic approach [5][15]

Core Viewpoint - Synthetic lethality drugs are emerging as a promising treatment strategy in oncology, allowing for the selective killing of cancer cells while sparing normal cells, with PARP inhibitors being a notable success in this field [1][6][7]. Industry Definition and Principles - Synthetic lethality refers to a biological phenomenon where mutations in two non-lethal genes do not affect cell survival individually, but simultaneous mutations lead to cell death. This principle is leveraged in cancer treatment to target specific pathways that cancer cells depend on [2][6]. - The concept of synthetic lethality has gained traction, particularly with the success of PARP inhibitors, which target DNA damage repair mechanisms [6][7]. Current Development Status - The global synthetic lethality drug market is projected to reach $4.3 billion in 2024, with China's market expected to grow to 3.6 billion yuan. By 2025, these figures are anticipated to rise to $4.8 billion globally and 4.6 billion yuan in China [1][7]. - The sales of PARP inhibitors reached $3.072 billion globally in 2024, showing a growth of approximately 9.3% after ten years on the market. Sales are expected to reach $3.4 billion by 2025 [1][7]. Industry Chain - The synthetic lethality drug industry chain includes upstream components such as biological raw materials, animal models, and chemical reagents; midstream focuses on drug research and production; and downstream applications are primarily in clinical settings, including hospitals and research institutions [8]. Competitive Landscape - Major companies in the synthetic lethality space include Hengrui Medicine and BeiGene, with several others like Clovis Oncology and AstraZeneca also involved. The market features a variety of PARP inhibitors, with ongoing research into additional synthetic lethality targets [2][9][10]. - The success of PARP inhibitors has led to increased interest in synthetic lethality as a viable strategy for cancer treatment, with multiple companies exploring this avenue [9][10]. Future Development - The role of synthetic lethality in modern cancer precision therapy is becoming increasingly significant, with ongoing research paving the way for new treatment avenues. Despite progress, challenges remain in the application of synthetic lethality in clinical settings [13][14].

Core Viewpoint - Nanjing Inpai Pharmaceutical Co., Ltd. has submitted its application for a mainboard listing on the Hong Kong Stock Exchange, with Goldman Sachs and CICC as joint sponsors. The company focuses on precision cancer therapies based on synthetic lethality, with its only commercial product being the PARP1/2 inhibitor, Senaparib, for first-line maintenance therapy in ovarian cancer [1][2]. Financial Performance - The financial data of Inpai Pharmaceutical reflects the typical characteristics of innovative drug companies, showing high investment and slow output. The projected revenues for 2023, 2024, and the first half of 2025 are 235 million, 34 million, and 25 million yuan respectively, with a significant year-on-year decline of 85.47% in 2024 due to reliance on technology licensing rather than direct product sales [2][3]. - The net losses for the same periods are 20 million, 255 million, and 129 million yuan, indicating that losses have not narrowed post-approval of Senaparib, but rather expanded. As of June 30, 2025, the company has only 210 million yuan in cash and cash equivalents, which is insufficient to sustain operations for more than a year given its annual R&D expenditure of approximately 200 million yuan [2][3]. Product Overview - Senaparib is the only commercialized product of Inpai Pharmaceutical, approved in January 2025 for first-line maintenance treatment in ovarian cancer. Clinical data shows it has a competitive edge, with a risk ratio of 0.43, indicating a 57% reduction in the risk of disease progression or death [3][4]. - Despite promising clinical data, market performance has been underwhelming, with Senaparib only available in 27 provinces and around 200 pharmacies as of June 30, 2025. The competitive landscape includes established PARP inhibitors like Olaparib and Niraparib, which have already gained market traction [3][4]. Market Competition - The PARP inhibitor market is becoming increasingly competitive, with nearly 40 PARP inhibitors in clinical development and four in Phase III trials. The company faces challenges in converting its product advantages into market share due to established clinical practices and hospital access barriers [4][5]. Future Prospects - Senaparib has been recommended for inclusion in the National Medical Insurance Drug List, with negotiations expected in the fourth quarter. Successful inclusion could boost sales but may compress profit margins, raising questions about the company's ability to achieve breakeven [4][5]. - Other products in Inpai's pipeline are in early stages, with a new generation PARP1 selective inhibitor currently in Phase I/II trials, unlikely to reach the market before 2030. The company will continue to rely heavily on Senaparib for revenue in the near term [5][6]. Funding and Valuation - Inpai Pharmaceutical has completed seven rounds of financing since its establishment in 2009, attracting notable investors. However, post-D+ round, the company's diluted valuation decreased from approximately 3.138 billion yuan to 2.823 billion yuan [7][8]. - A redemption right was triggered for 24,089,597 shares, indicating potential issues related to the company's IPO timeline or other significant operational challenges, although specific reasons were not disclosed in the prospectus [7][8].

Core Viewpoint - Nanjing Inpai Pharmaceutical Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, marking its entry into the innovative drug sector focused on synthetic lethality mechanisms for cancer treatment [1] Company Overview - Established in 2009, Inpai Pharmaceutical is a commercial-stage biotechnology company specializing in precision cancer therapies based on synthetic lethality [1] - The company is one of only three globally that possesses both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors [1][7] Financial Performance - In 2023, 2024, and the first half of 2025, the company recorded losses of approximately RMB 199 million, RMB 255 million, and RMB 129 million, respectively, primarily due to high R&D expenditures [2][3] - As of June 30, 2025, the company had cash and cash equivalents of RMB 21 million, indicating a tightening cash flow situation [2] Product Development and Commercialization - The core product, Senaparib, received approval in January 2025 for first-line maintenance treatment of ovarian cancer in China, showing the largest progression-free survival benefit among its peers [3][4] - As of June 30, 2025, Senaparib has been launched in 27 provinces in China and is available in over 200 direct-to-patient pharmacies and more than 600 medical institutions [4] - The product is expected to be included in the National Medical Insurance Drug List in early 2026, enhancing its market penetration [4] Market Potential and Competitive Landscape - The synthetic lethality mechanism is gaining recognition in clinical settings, with significant potential for market expansion due to its targeted approach and ability to overcome drug resistance [6][9] - The global market for synthetic lethality drugs is projected to reach USD 8.7 billion by 2029, while the small molecule targeted tumor drug market is expected to reach USD 105.8 billion in the same period [9] - Inpai Pharmaceutical has established a leading position in the synthetic lethality space, with a diverse pipeline that includes one commercial-stage drug, four clinical-stage drugs, and seven pre-IND drugs [7][9] Challenges and Future Outlook - The competitive landscape is intensifying, with nearly 40 PARP inhibitors in clinical development, highlighting the need for Inpai to maintain its competitive edge [7][9] - Despite the challenges, the rapid commercialization of Senaparib and its clinical advantages position the company for potential revenue growth and market success [10]

Group 1: Market Overview - The Hang Seng Healthcare Index (HSCICH) decreased by 2.76% during the week, while the Hong Kong Innovation Drug ETF (513120) fell by 1.60% [4] - The pharmaceutical and biotechnology index dropped by 1.69%, underperforming the Shanghai Composite Index by 1.04 percentage points [4] Group 2: Company Developments - Nanjing Inpai Pharmaceutical Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange, reporting a net loss of 129 million yuan in the first half of the year [5][6] - Inpai's core product, Senapali, was approved for marketing in China as a first-line maintenance therapy for ovarian cancer, applicable to all populations [6] - Inpai's revenue projections for 2023, 2024, and the first half of 2025 are 235 million yuan, 34 million yuan, and 25 million yuan respectively, with net losses of 20 million yuan, 255 million yuan, and 129 million yuan [6][7] Group 3: Clinical Trials and Innovations - The first subcutaneous antibody-drug conjugate (ADC) for advanced non-small cell lung cancer has entered Phase II clinical trials [8][16] - JSKN033, a subcutaneous ADC, aims to simplify administration time and reduce risks associated with intravenous delivery [18] - The National Medical Products Administration disclosed 117 new clinical trial registrations, with 29 in Phase II or higher, focusing on oncology and autoimmune diseases [8] Group 4: Stock Performance and Market Sentiment - Yimeng Bio-B experienced a significant decline, attributed to overall adjustments in the innovation drug sector and the upcoming lock-up expiration for cornerstone investors [12][13] - Yimeng Bio-B's stock price has seen a 30% drop from its peak, despite being up approximately 279% since its IPO [13] - Analysts from GF Securities and Morgan Stanley have set target prices for Yimeng Bio-B at 574.28 HKD and 766 HKD per share, respectively, citing its leading ADC platform and partnerships with global firms [13][15]

IMPACT Therapeutics, Inc. 南京英派藥業股份有限公司 （於中華人民共和國成立的股份有限公司） 的申請版本 香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向南京英派藥業股份有限公司（「本公司」）、其聯席保薦人、整體協調人、顧問或包銷團 成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，本公司 不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依 據呈交香港公司註冊處註冊的本公司招股章程作出投資決定；該招股章程的副本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供 ...

Core Viewpoint - Crystal Technology (晶泰科技) announced a significant milestone in clinical research for the next-generation PRMT5 inhibitor PEP08, which has received clinical trial approvals from regulatory bodies in Australia and Taiwan, marking the initiation of Phase I clinical trials [1][3]. Group 1: Clinical Development - PEP08 has been approved for clinical trials by the Human Research Ethics Committee (HREC) in Australia, the Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA) [1]. - The approval signifies a major step forward in the collaboration between Crystal Technology and PharmaEngine, leading to milestone payments for Crystal Technology [1][3]. Group 2: Drug Characteristics - PRMT5 is a key enzyme overexpressed in various cancers, and inhibiting its activity can lead to a "synthetic lethality" effect in tumors with homozygous deletion of MTAP, which accounts for approximately 10-15% of human cancers [1]. - PEP08, as a second-generation PRMT5 inhibitor, exhibits high activity and selectivity, forming a stable ternary complex with PRMT5, specifically targeting MTAP-deficient tumor cells while minimizing effects on normal cells [2][3]. Group 3: Preclinical Research - Preclinical data indicate that PEP08 shows significant advantages in toxicity and safety compared to first-generation non-selective PRMT5 inhibitors, with good blood-brain barrier penetration and ideal overall drug-like properties [3]. - PEP08 demonstrates strong in vivo efficacy at lower doses in multiple animal efficacy models, suggesting potential best-in-class effects and broad potential for combination with other therapies [3].